In Boston, life expectancy can differ by up to 23 years between neighborhoods located just miles apart. To help address this, we’re investing $2 million through our Alnylam Challengers program to support frontline Care Navigators who help the hardest to reach patients in underserved communities access vital social and medical services. Together with leading institutions Boston Children's Hospital, Boston Medical Center (BMC), and Whittier Street Health Center, we’re working to reduce disparities and improve health outcomes for those who need it most. Learn more about this new program: https://bit.ly/4pgF07k #AlnylamChallengers #CareNavigation #BostonHealth #CorporateResponsibility
Alnylam Pharmaceuticals
Biotechnology Research
Cambridge, Massachusetts 257,343 followers
Alnylam is the leading RNAi therapeutics company. We're a fast-growing biopharma with a deep pipeline and global reach.
About us
SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, four more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,500+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email medinfo@alnylam.com or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861 Fraudulent Recruitment Activity Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in “@alnylam.com.”
- Website
-
http://www.alnylam.com
External link for Alnylam Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2002
- Specialties
- Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, and RNAi
Locations
Employees at Alnylam Pharmaceuticals
Updates
-
For Healthcare Professionals: When it comes to transthyretin amyloidosis with cardiomyopathy (ATTR-CM), progression can be fast and detrimental. If you suspect a patient may have ATTR-CM, a timely diagnosis is essential. Learn how to confirm or rule out ATTR-CM: https://bit.ly/3LJtumq
-
This #VeteransDay, we honor the courage and commitment of all who have served, especially the veterans within our Alnylam community. Your service inspires us, and your continued contributions make us #AlnylamProud. Thank you.
-
-
🔗 https://bit.ly/3DEiiUB Doctors appointments, tests, pharmacy visits, medication routines - the sounds of these things make living with disease noisy. But when disease is silenced, these things become less prevalent and the everyday joys of life can be amplified. We've pioneered #RNAi therapeutics to do just that - #SilenceDisease to #AmplifyLife.
-
The Alnylam Assist® program offers support services to patients who are prescribed one of our products. Our team of experts are here to help patients access and understand treatment. https://bit.ly/3URXbSy
-
Alnylam Pharmaceuticals reposted this
We continue to make exceptional progress in this landmark year for Alnylam Pharmaceuticals, as we highlighted today in our third-quarter earnings report. The U.S. launch of AMVUTTRA is off to a fantastic start, with all launch indicators flashing green. We are advancing promising programs all across our pipeline, and we are poised to achieve sustainable profitability. We are building an incredible company with the potential to deliver for patients for years to come.
-
Women's pain is often blamed on stress, hormones, or branded as "normal," which can lead to delayed diagnosis of serious conditions. That was the case for Donna, whose journey to a diagnosis of acute hepatic #porphyria (AHP) spanned over 10 years. Recognizing and investigating seemingly disparate symptoms such as those experienced by people with AHP can help patients like Donna regain control of their lives. Read more about her symptoms and story: https://bit.ly/3Xs0KBp #raredisease #womenshealth
-
-
As we approach #WorldAmyloidosisDay, the voices of those living with ATTR amyloidosis and those who care for them remind us that optimal care should reflect individual needs, beyond the clinical symptoms of disease. At Alnylam, we’re proud to help raise awareness with, and on behalf of, the community.
-
🔗 https://bit.ly/3FsFgOW It's her big game. You want to be there AND be fully present. Living with disease makes that difficult by holding you back. Over time, the sounds of disease - doctor visits, tests, managing medication, saying “no” to life’s most important moments - mute the joy of life. But what happens when you #SilenceDisease? #AmplifyLife #RNAi #RNAiTherapeutics
-
From discovery to delivery, it takes many hands, and hearts, to bring our medicines to patients. Recently, a patient from the TTR community visited our partner, KINOVATE LIFE SCIENCES, INC, which specializes in oligonucleotide material supply essential to making our medicines. Hearing directly from patients brings powerful perspective to our work and reinforces the shared purpose that unites us. Thank you to our partners at Kinovate and to the patient community for inspiring all of us at Alnylam.